Literature DB >> 10722253

Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjögren's syndrome.

A K Halse1, M C Marthinussen, M Wahren-Herlenius, R Jonsson.   

Abstract

In this study an ELISA assay was used to quantify the levels of antibodies against the recombinant Ro 52 kD, Ro 60 kD, and La 48 kD proteins in plasma and saliva of 17 Sjögren's syndrome patients. The levels of total IgG, IgA, and IgM were also quantified. About one third of the patients had salivary enrichment of IgA and IgM against the Ro 52 kD, Ro 60 kD, and La 48 kD antigens and IgG against La 48 kD, while no enrichment of IgG against Ro 52 kD and Ro 60 kD was found. Most correlations between plasma and saliva levels of antigen specific antibodies were highly significant, as were most correlations between focus score and levels of antigen specific antibodies in plasma and saliva. In total, the results support the hypothesis that autoantibodies are produced in the salivary glands. The strong correlation between focus score and plasma and saliva levels of autoantibodies, indicates that the local autoantibody production is a consequence of local inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722253     DOI: 10.1080/030097400750001752

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  13 in total

1.  Progression of salivary gland dysfunction in patients with Sjogren's syndrome.

Authors:  J Pijpe; W W I Kalk; H Bootsma; F K L Spijkervet; C G M Kallenberg; A Vissink
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 2.  Salivary biomarkers for clinical applications.

Authors:  Lei Zhang; Hua Xiao; David T Wong
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Authors:  Tamer I Mahmoud; Jingya Wang; Jodi L Karnell; Qiming Wang; Shu Wang; Brian Naiman; Phillip Gross; Philip Z Brohawn; Chris Morehouse; Jordan Aoyama; Clive Wasserfall; Laura Carter; Mark A Atkinson; David V Serreze; Helen Braley-Mullen; Tomas Mustelin; Roland Kolbeck; Ronald Herbst; Rachel Ettinger
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

4.  The Sjögren's syndrome-associated autoantigen Ro52/TRIM21 modulates follicular B cell homeostasis and immunoglobulin production.

Authors:  S Brauner; M Ivanchenko; G E Thorlacius; A Ambrosi; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2018-10-16       Impact factor: 4.330

5.  Secretory autoantibodies in primary biliary cirrhosis (PBC).

Authors:  J M Palmer; M Doshi; J A Kirby; S J Yeaman; M F Bassendine; D E Jones
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

6.  Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjögren's syndrome.

Authors:  E Toker; S Yavuz; H Direskeneli
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

Review 7.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

8.  Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival.

Authors:  Ewa A Szyszko; Karl A Brokstad; Gunnvor Oijordsbakken; Malin V Jonsson; Roland Jonsson; Kathrine Skarstein
Journal:  Arthritis Res Ther       Date:  2011-01-07       Impact factor: 5.156

9.  Difference in clinical presentation between women and men in incident primary Sjögren's syndrome.

Authors:  Jorge I Ramírez Sepúlveda; Marika Kvarnström; Susanna Brauner; Chiara Baldini; Marie Wahren-Herlenius
Journal:  Biol Sex Differ       Date:  2017-05-12       Impact factor: 5.027

Review 10.  Tertiary Lymphoid Structures: Autoimmunity Goes Local.

Authors:  Elena Pipi; Saba Nayar; David H Gardner; Serena Colafrancesco; Charlotte Smith; Francesca Barone
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.